The long-term beneficial effects of ursodeoxycholic acid in primary biliary cirrhosis are highly questionable [15]

American Journal of Gastroenterology

Volumn 102, Issue 2, 2007, Pages 464-465

  Yan, Gong ^a   Erik, Christensen ^b   Gluud, Christian ^c  

^a University of Copenhagen   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

URSODEOXYCHOLIC ACID;

CHEMICAL ANALYSIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LETTER; LIVER TRANSPLANTATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME;

CHOLAGOGUES AND CHOLERETICS; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS, BILIARY; META-ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 33846478658     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00904_15.x     Document Type: Letter

References (5)

1. Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: A meta-analysis of randomized controlled trials. Am J Gastroenterol 2006;101:1529-38.
2. Higgins JPT, Green S, eds. Cochrane reviewers' handbook 4.2.5 [updated May 2005]. In: The Cochrane library, issue 3. Chichester, UK: John Wiley & Sons, Ltd., 2005.
3. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2001, issue 4. Art. No.: CD000551. DOI: 10.1002/14651858.CD000551.
4. Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years. Gastroenterology 2002;123:1044-51.
5. Gamble C, Hollis S. Uncertainty method improved on best/worst case analysis in a binary meta-analysis. J Clin Epidemiol 2005;58:579-88.